Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Ophthalmology

Retrieve available abstracts of 54 articles:
HTML format
Text format



Single Articles


    May 2018
  1. KLEIN R, Lee KE, Danforth L, Tsai MY, et al
    The Relationship of Retinal Vessel Geometric Characteristics to the Incidence and Progression of Diabetic Retinopathy.
    Ophthalmology. 2018 May 17. pii: S0161-6420(18)30530.
    PubMed     Text format     Abstract available


  2. WONG TY, Sun J, Kawasaki R, Ruamviboonsuk P, et al
    Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.
    Ophthalmology. 2018 May 15. pii: S0161-6420(17)33523.
    PubMed     Text format     Abstract available


  3. REDDY RK, Pieramici DJ, Gune S, Ghanekar A, et al
    Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Ophthalmology. 2018 May 8. pii: S0161-6420(17)33607.
    PubMed     Text format     Abstract available


  4. PAYNE JF, Clark WL, Bruce BB, Wykoff CC, et al
    Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
    Ophthalmology. 2018 May 2. pii: S0161-6420(18)30678.
    PubMed     Text format    


    March 2018
  5. LIN J, Chang JS, Yannuzzi NA, Smiddy WE, et al
    Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 29. pii: S0161-6420(18)30040.
    PubMed     Text format     Abstract available


  6. OBEID A, Gao X, Ali FS, Talcott KE, et al
    Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
    Ophthalmology. 2018 Mar 29. pii: S0161-6420(17)33569.
    PubMed     Text format     Abstract available


  7. YANNUZZI NA, Sridhar J, Chang JS, Lin J, et al
    Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 20. pii: S0161-6420(18)30299.
    PubMed     Text format    


  8. GUPTA P, Liang Gan AT, Kidd Man RE, Fenwick EK, et al
    Impact of Incidence and Progression of Diabetic Retinopathy on Vision-Specific Functioning.
    Ophthalmology. 2018 Mar 20. pii: S0161-6420(17)32967.
    PubMed     Text format     Abstract available


  9. JAMPOL LM, Glassman AR, Liu D, Aiello LP, et al
    Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Ophthalmology. 2018 Mar 7. pii: S0161-6420(17)32232.
    PubMed     Text format     Abstract available


  10. KRAUSE J, Gulshan V, Rahimy E, Karth P, et al
    Grader Variability and the Importance of Reference Standards for Evaluating Machine Learning Models for Diabetic Retinopathy.
    Ophthalmology. 2018 Mar 2. pii: S0161-6420(17)32698.
    PubMed     Text format     Abstract available


    February 2018
  11. LIU L, Tham YC
    Re: Keel et al.: The prevalence of diabetic retinopathy in Australian adults with self-reported diabetes: The National Eye Health Survey (Ophthalmology. 2017;124:977-984).
    Ophthalmology. 2018;125:e13-e14.
    PubMed     Text format    


    January 2018
  12. FIGUEIRA J, Fletcher E, Massin P, Silva R, et al
    Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
    Ophthalmology. 2018 Jan 27. pii: S0161-6420(17)32188.
    PubMed     Text format     Abstract available


  13. BROWN DM, Ou WC, Wong TP, Kim RY, et al
    Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Ophthalmology. 2018 Jan 11. pii: S0161-6420(17)31641.
    PubMed     Text format     Abstract available


  14. GRZYBOWSKI A, Kanclerz P
    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e8-e9.
    PubMed     Text format    


  15. JONNA G, Kim SJ
    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e4.
    PubMed     Text format    


  16. MODJTAHEDI BS, Fong DS
    Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
    Ophthalmology. 2018;125:e10-e11.
    PubMed     Text format    


    December 2017
  17. TAN GS, Gan A, Sabanayagam C, Tham YC, et al
    Ethnic Differences in the Prevalence and Risk Factors of Diabetic Retinopathy: The Singapore Epidemiology of Eye Diseases Study.
    Ophthalmology. 2017 Dec 4. pii: S0161-6420(17)31893.
    PubMed     Text format     Abstract available


  18. THOMAS M, Rao RC, Johnson MW, Paulus YM, et al
    Re: Bressler et al.: Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab (Ophthalmology. 2017;124:431-439).
    Ophthalmology. 2017;124:e87-e88.
    PubMed     Text format    


    September 2017
  19. ZUR D, Iglicki M, Busch C, Invernizzi A, et al
    Optical Coherence Tomography Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant.
    Ophthalmology. 2017 Sep 18. pii: S0161-6420(17)32014.
    PubMed     Text format     Abstract available


  20. OLSEN TW, Lum F
    Re: Wang et al.: Incidence and risk factors for developing diabetic retinopathy among youths with type 1 or type 2 diabetes throughout the United States (Ophthalmology. 2017;124:424-430).
    Ophthalmology. 2017;124:e68-e69.
    PubMed     Text format    


    July 2017
  21. DHOOT DS, Baker K, Saroj N, Vitti R, et al
    Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
    Ophthalmology. 2017 Jul 29. pii: S0161-6420(17)31292.
    PubMed     Text format     Abstract available


    June 2017
  22. JIANG Y, Lim J, Degillio A
    Profound Macular Ischemia on Optical Coherence Tomography Angiography in Severe Diabetic Retinopathy.
    Ophthalmology. 2017;124:785.
    PubMed     Text format    


    April 2017
  23. VENKATESH P
    Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359).
    Ophthalmology. 2017;124:e37-e38.
    PubMed     Text format    


  24. CHEW EY
    Screening for Diabetic Retinopathy in Youth-Onset Diabetes.
    Ophthalmology. 2017;124:422-423.
    PubMed     Text format    


    March 2017
  25. GARGEYA R, Leng T
    Automated Identification of Diabetic Retinopathy Using Deep Learning.
    Ophthalmology. 2017 Mar 27. pii: S0161-6420(16)31774.
    PubMed     Text format     Abstract available


  26. SILVA PS, El-Rami H, Barham R, Gupta A, et al
    Hemorrhage and/or Microaneurysm Severity and Count in Ultrawide Field Images and Early Treatment Diabetic Retinopathy Study Photography.
    Ophthalmology. 2017 Mar 20. pii: S0161-6420(16)32199.
    PubMed     Text format     Abstract available


  27. KEEL S, Xie J, Foreman J, van Wijngaarden P, et al
    The Prevalence of Diabetic Retinopathy in Australian Adults with Self-Reported Diabetes: The National Eye Health Survey.
    Ophthalmology. 2017 Mar 15. pii: S0161-6420(16)32256.
    PubMed     Text format     Abstract available


  28. IP MS, Zhang J, Ehrlich JS
    The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
    Ophthalmology. 2017 Mar 8. pii: S0161-6420(16)31292.
    PubMed     Text format     Abstract available


  29. SINGH RP, Lehmann R, Martel J, Jong K, et al
    Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.
    Ophthalmology. 2017 Mar 4. pii: S0161-6420(16)31411.
    PubMed     Text format     Abstract available


  30. TORNAMBE P
    Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358).
    Ophthalmology. 2017;124:e25-e26.
    PubMed     Text format    


    February 2017
  31. BRESSLER SB, Beaulieu WT, Glassman AR, Gross JG, et al
    Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Ophthalmology. 2017 Feb 1. pii: S0161-6420(16)31179.
    PubMed     Text format     Abstract available


    January 2017
  32. WYKOFF CC, Chakravarthy U, Campochiaro PA, Bailey C, et al
    Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Ophthalmology. 2017 Jan 9. pii: S0161-6420(16)31433.
    PubMed     Text format     Abstract available


  33. SHANMUGAM MP, Harshey KB, Ramanjulu R, Mishra DK, et al
    Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359).
    Ophthalmology. 2017;124:e5.
    PubMed     Text format    


  34. AZAD S, Takkar B
    Re: Sadiq et al.: Effect of vitreomacular adhesion on treatment outcomes in the ranibizumab for edema of the macula in diabetes (READ-3) study (Ophthalmology 2016;123:324-329).
    Ophthalmology. 2017;124:e12-e13.
    PubMed     Text format    


    December 2016
  35. CHONG YH, Fan Q, Tham YC, Gan A, et al
    Type 2 Diabetes Genetic Variants and Risk of Diabetic Retinopathy.
    Ophthalmology. 2016 Dec 27. pii: S0161-6420(16)30930.
    PubMed     Text format     Abstract available


  36. TUFAIL A, Rudisill C, Egan C, Kapetanakis VV, et al
    Automated Diabetic Retinopathy Image Assessment Software: Diagnostic Accuracy and Cost-Effectiveness Compared with Human Graders.
    Ophthalmology. 2016 Dec 23. pii: S0161-6420(16)32018.
    PubMed     Text format     Abstract available


  37. SHARMA S, Kwan S, Fallano KA, Wang J, et al
    Comparison of Visual Outcomes of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with and without Diabetes Mellitus.
    Ophthalmology. 2016 Dec 22. pii: S0161-6420(16)31490.
    PubMed     Text format     Abstract available


  38. HE J, Xu X, Zhu J, Zhu B, et al
    Lens Power, Axial Length-to-Corneal Radius Ratio, and Association with Diabetic Retinopathy in the Adult Population with Type 2 Diabetes.
    Ophthalmology. 2016 Dec 16. pii: S0161-6420(16)31879.
    PubMed     Text format     Abstract available


  39. CHOUDHRY N, Golding J, Rao RC
    Vitreous Invasion: Neovascular Frond in Proliferative Diabetic Retinopathy.
    Ophthalmology. 2016;123:2625.
    PubMed     Text format    


    November 2016
  40. WANG SY, Andrews CA, Herman WH, Gardner TW, et al
    Incidence and Risk Factors for Developing Diabetic Retinopathy among Youths with Type 1 or Type 2 Diabetes throughout the United States.
    Ophthalmology. 2016 Nov 30. pii: S0161-6420(16)30997.
    PubMed     Text format     Abstract available


  41. SAMARA WA, Shahlaee A, Adam MK, Khan MA, et al
    Quantification of Diabetic Macular Ischemia Using Optical Coherence Tomography Angiography and Its Relationship with Visual Acuity.
    Ophthalmology. 2016 Nov 22. pii: S0161-6420(16)31634.
    PubMed     Text format     Abstract available


  42. PAYNE JF, Wykoff CC, Clark WL, Bruce BB, et al
    Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes.
    Ophthalmology. 2016 Nov 8. pii: S0161-6420(16)31353.
    PubMed     Text format     Abstract available


    October 2016
  43. NGUYEN HV, Tan GS, Tapp RJ, Mital S, et al
    Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore.
    Ophthalmology. 2016 Oct 7. pii: S0161-6420(16)30975.
    PubMed     Text format     Abstract available


  44. FINE SL, Goldberg MF, Tasman W
    Historical Perspectives on the Management of Macular Degeneration, Diabetic Retinopathy, and Retinal Detachment: Personal Reminiscences.
    Ophthalmology. 2016;123.
    PubMed     Text format     Abstract available


  45. SEPAH YJ, Sadiq MA, Boyer D, Callanan D, et al
    Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.
    Ophthalmology. 2016 Oct 1. pii: S0161-6420(16)31070.
    PubMed     Text format     Abstract available


    September 2016
  46. HEIER JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, et al
    Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Ophthalmology. 2016 Sep 17. pii: S0161-6420(16)30738.
    PubMed     Text format     Abstract available


  47. FERRIS FL 3RD, Nathan DM
    Preventing Diabetic Retinopathy Progression.
    Ophthalmology. 2016;123:1840-2.
    PubMed     Text format    


    August 2016
  48. BALARATNASINGAM C, Inoue M, Ahn S, McCann J, et al
    Visual Acuity Is Correlated with the Area of the Foveal Avascular Zone in Diabetic Retinopathy and Retinal Vein Occlusion.
    Ophthalmology. 2016 Aug 11. pii: S0161-6420(16)30657.
    PubMed     Text format     Abstract available


    July 2016
  49. LIN J, Chang JS, Smiddy WE
    Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
    Ophthalmology. 2016 Jul 14. pii: S0161-6420(16)30404.
    PubMed     Text format     Abstract available


  50. BURGESS PI, Harding SP, Garcia-Finana M, Beare NA, et al
    First Prospective Cohort Study of Diabetic Retinopathy from Sub-Saharan Africa: High Incidence and Progression of Retinopathy and Relationship to Human Immunodeficiency Virus Infection.
    Ophthalmology. 2016 Jul 9. pii: S0161-6420(16)30409.
    PubMed     Text format     Abstract available


    May 2016
  51. CAMPOCHIARO PA, Khanani A, Singer M, Patel S, et al
    Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
    Ophthalmology. 2016 May 25. pii: S0161-6420(16)30201.
    PubMed     Text format     Abstract available


  52. SINGH RP, Habbu K, Ehlers JP, Lansang MC, et al
    The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema.
    Ophthalmology. 2016 May 24. pii: S0161-6420(16)30084.
    PubMed     Text format     Abstract available


  53. WYKOFF C, Elman MJ, Regillo C, Ding B, et al
    Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials.
    Ophthalmology. 2016 May 18. pii: S0161-6420(16)30097.
    PubMed     Text format     Abstract available


    February 2016
  54. SOPHIE R, Lu N, Campochiaro PA
    Reply.
    Ophthalmology. 2016;123:e12-3.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: